Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27%
09.02.2022 - -FC2 Prescription Business Entering 6th Year of Growth - -FDA Approves Company’s ENTADFI, New Treatment for Benign Prostatic Hyperplasia with Commercialization Plans Underway- -Company Enters into Clinical Trial ...
Source: wallstreet-online.de